Retatrutide
- Status
- Phase 3, , not approved for human use
- Evidence
Human phase 3, not approved, graded on the Fat Loss Peptides Bench
Retatrutide (development code LY3437943) is an investigational once-weekly agonist at three receptors: GLP-1, GIP and glucagon. It is Eli Lilly's third-generation incretin-based therapy.
Reviewed
01Overview
What Retatrutide is
Semaglutide activates GLP-1 alone and tirzepatide activates GLP-1 and GIP; retatrutide adds glucagon receptor agonism, for synergistic effects on energy expenditure, hepatic lipid metabolism and weight reduction.
Read the full overviewShow less
As of September 2026, retatrutide is not FDA-approved. Its Phase 3 program covers obesity (the TRIUMPH trials), type 2 diabetes (the TRANSCEND-T2D trials), fatty liver disease, and cardiovascular and kidney outcomes. In the lead obesity trial, TRIUMPH-1 (NEJM, 29 September 2026), mean weight loss at 80 weeks was 25.0% on 12 mg against 3.9% on placebo for everyone randomized (treatment-regimen estimand). Lilly's 21 May 2026 topline gave 28.3% for the efficacy estimand, which assumes everyone stayed on treatment.
The clinical excitement rests on the Phase 2 obesity trial published in NEJM in 2023: on 12 mg weekly, participants lost a mean 24.2% of body weight at 48 weeks, more than the main trials of semaglutide (~15% at 68 weeks in STEP-1) and tirzepatide (~21% at 72 weeks in SURMOUNT-1) had shown ([Jastreboff et al., 2023]).
The efficacy signal is strong, but the triple-receptor profile carries distinct safety considerations beyond the GLP-1 class:
- Heart rate rises a mean ~6-8 bpm, more than on semaglutide or tirzepatide, likely because of the glucagon-receptor component.
- GI adverse events are more frequent at the 12 mg maximal dose than at lower doses or on GLP-1-only agents.
- Long-term cardiovascular outcomes are unknown; the large Phase 3 cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes, is still running.
It is not FDA-approved and is available only through clinical trials, Eli Lilly's pre-approval expanded access program (requested by a physician, for adults with a BMI of 35 or more and serious obesity-related complications who have run out of approved options and cannot join a trial), research-chemical channels and (controversially) compounding pharmacies in some jurisdictions that use non-commercial retatrutide sourcing. Lilly plans to submit it to the FDA in the first quarter of 2027.
Typical dosing, extrapolated from the Phase 2 uptitration schedule, starts at 2 mg weekly SC and titrates to 8-12 mg weekly over 12-20 weeks. The 12 mg weekly maximum is associated with both the largest weight loss and the largest side-effect burden. The Retatrutide Dosage Guide covers uptitration, and Semaglutide vs Tirzepatide vs Retatrutide helps with choosing between the three.
How it works
Retatrutide is a 39-amino-acid synthetic peptide with balanced agonist activity at three receptors: GLP-1R, GIPR and GCGR (the glucagon receptor). A C20 fatty diacid side chain (similar to semaglutide's) binds it to albumin and extends its plasma half-life to ~6 days, which allows once-weekly subcutaneous dosing.
Read the full mechanismShow less
1. GLP-1 receptor agonism (Gs / cAMP pathway on pancreatic beta cells and CNS)
- Activating GLP-1R on pancreatic β-cells drives glucose-dependent insulin secretion.
- On hypothalamic POMC/NPY/AgRP neurons, GLP-1R activation suppresses appetite.
- Slower gastric emptying reduces postprandial glucose excursion and prolongs satiety.
- Semaglutide, tirzepatide and liraglutide share the mechanism.
EC₅₀ at human GLP-1R is close to semaglutide's.
2. GIP receptor agonism (Gs / cAMP pathway on pancreatic beta cells and adipose tissue)
- GIPR activation on pancreatic β-cells enhances glucose-dependent insulin secretion.
- In adipose tissue, GIPR has complex effects on lipid storage and energy expenditure.
- It adds to the GLP-1 effect on insulin secretion and satiety.
- Tirzepatide, the "twincretin", uses the same mechanism.
At GIPR, EC₅₀ is comparable to tirzepatide's.
3. Glucagon receptor agonism: the retatrutide signature (Gs / cAMP pathway on hepatocytes and adipose tissue)
This is what distinguishes retatrutide from semaglutide and tirzepatide:
- Activating GCGR on hepatocytes raises hepatic glucose output, which the GLP-1 and GIP actions offset; trials report net falls in glucose and HbA1c.
- In hepatocytes it also stimulates fatty acid oxidation and cuts lipid accumulation, the likely mechanism for retatrutide's strong NAFLD effects.
- On adipose tissue, GCGR activation enhances lipolysis and energy expenditure (a measurable ~3-5% increase in resting metabolic rate in Phase 2).
- In the hypothalamus, GCGR activation adds further appetite suppression.
The glucagon component is the reason retatrutide produces greater weight loss than GLP-1 + GIP alone: glucagon drives direct lipolysis and raises energy expenditure on top of the appetite suppression from GLP-1/GIP. Side by side:
| Effect | GLP-1 (semaglutide) | GLP-1 + GIP (tirzepatide) | GLP-1 + GIP + GCG (retatrutide) |
|---|---|---|---|
| Appetite suppression | Strong | Strong+ | Strong++ |
| Insulin secretion | Enhanced | Enhanced+ | Enhanced+ |
| Gastric emptying delay | Strong | Strong | Strong |
| Lipolysis | Indirect (via caloric deficit) | Modest direct effect | Strong direct effect |
| Energy expenditure | Neutral | Slight increase | +3-5% REE |
| Hepatic fat reduction | Modest | Moderate | Strong |
4. Balanced agonist design
Retatrutide was designed as a balanced triple agonist, with relative potencies at GLP-1R, GIPR and GCGR within one order of magnitude of each other. Earlier experimental triple agonists were biased toward one receptor. The balance enables the clinical profile observed in Phase 2.
5. Pharmacokinetics
- Plasma half-life: ~6 days (albumin binding via the C20 fatty diacid)
- Steady state: reached after ~4 weeks of weekly dosing
- Dosing: once-weekly subcutaneous injection
- Distribution: extensive albumin binding; moderate CNS penetration, enough for central appetite-suppressive effects
- Clearance: predominantly hepatic, with minimal renal excretion
Characterized in Phase 1 by [Urva et al., 2022].
6. Secondary mechanisms under investigation
- Glucagon agonism likely activates brown adipose tissue (BAT), which may contribute to the rise in energy expenditure.
- GLP-1, GIP and GCG all signal at hypothalamic energy-sensing neurons in the CNS, and triple activation may produce qualitatively different satiety signaling than GLP-1 alone.
Triple agonism: why 3 receptors matter
GLP-1 Receptor
Suppresses appetite, enhances insulin secretion, slows gastric emptying. Same pathway as semaglutide.
GIP Receptor
Modulates lipid metabolism and adipose tissue function. Combined with GLP-1 in tirzepatide.
Glucagon Receptor
Key differentiator from semaglutide and tirzepatide. Drives hepatic fat oxidation and can raise energy expenditure (animal models and short human glucagon studies).
Studied for
- Obesity
- Type 2 diabetes
- Metabolic syndrome
- NASH
Benefits listed
- Body weight reduction up to 24% at 48 weeks (Phase 2 data)
- Glycemic control in T2DM: HbA1c reduction similar to tirzepatide
- Hepatic fat reduction: potential MASH/NAFLD therapeutic effect
- Modest increase in resting energy expenditure (3-5%)
Show 4 moreShow less
- Preferential visceral fat reduction
- Blood pressure and lipid profile improvement (secondary to weight loss)
- Once-weekly dosing convenience
- Mean weight loss of 25.0% at 80 weeks on 12 mg in the Phase 3 TRIUMPH-1 trial for everyone randomized (treatment-regimen estimand, NEJM 2026); 28.3% in Lilly's efficacy-estimand topline
02Research
Free with emailWhat the research shows
Graded on a research bench
Reference pages that put Retatrutide next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Phase 2 trial data: weight loss results
Eli Lilly's Phase 2 trial (n=338, published in NEJM 2023) tested retatrutide at doses from 1mg to 12mg weekly over 48 weeks in adults with obesity (BMI 30 or more) or overweight (BMI 27 or more) with at least one weight-related condition.
- Mean weight loss at 12mg (48 wk)
- 24.2%
- 12mg group losing 30% or more of body weight (48 wk)
- 26%
- Liver fat cut at 12mg (48 wk)
- 86%
Dose-Response Weight Loss at 48 Weeks (low/high = 2 mg or 4 mg starting dose)
- 1 mg-8.7%
- 4 mg (low)-16.3%
- 4 mg (high)-17.8%
- 8 mg (low)-21.7%
- 8 mg (high)-23.9%
- 12 mg-24.2%
Phase 3: TRIUMPH-1 reported 28.3% average weight loss at 80 weeks on the 12 mg dose (May 2026), and TRIUMPH-2 and TRIUMPH-3 also met their primary endpoints (July 2026). Eli Lilly plans to submit retatrutide to the FDA in Q1 2027.
Retatrutide vs Tirzepatide vs Semaglutide
| Compound | Targets | Max Weight Loss | Trial | Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | STEP-1 (68 wk) | FDA Approved |
| Tirzepatide | GLP-1 + GIP | ~22.5% | SURMOUNT-1 (72 wk) | FDA Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~28.3% | TRIUMPH-1 (80 wk) | Phase 3 |
Cross-trial comparisons: interpret with caution due to study population differences.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Retatrutide side effects and interactions
Side effects
Moderate riskStop use if
- Long-term safety profile still being established; Phase 3 trials are still running
- Thyroid tumor history
- Severe GI events
Who should not use it
Contraindications
Absolute contraindications
- A personal or family history of medullary thyroid carcinoma (MTC) rules it out, given the GLP-1 class rodent carcinogenicity signal.
- So does Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), on the same signal.
- With a history of acute pancreatitis, retatrutide carries a recurrence risk (a GLP-1 class signal).
- The GLP-1 class worsens active gallbladder disease or acute cholecystitis.
- Active malignancy is relative to absolute depending on type; the GLP-1 class has some residual oncology concerns.
- With no safety data, avoid it in pregnancy or when planning pregnancy.
- Breastfeeding has no safety data either.
- No pediatric data exist for retatrutide (age <18). Some GLP-1 class drugs have pediatric obesity approvals; retatrutide does not.
- The GLP-1 mechanism would dramatically worsen severe gastroparesis or gastric outlet obstruction.
Read all the contraindications and cautionsShow less
Relative contraindications (consult physician before use)
- A history of chronic pancreatitis raises recurrence risk.
- Rapid glycemic correction can worsen active proliferative diabetic retinopathy.
- Investigate the cause of resting tachycardia (HR >90 at baseline) first, since retatrutide consistently raises HR.
- Data in severe heart failure (NYHA III-IV) are limited, and the heart rate elevation may be problematic.
- Appetite suppression is dangerous with an active eating disorder (anorexia nervosa or bulimia).
- Severe hepatic impairment (Child-Pugh C) matters because hepatic clearance is primary.
- Data in severe chronic kidney disease (eGFR <30) are limited.
Drug interactions
- Sulfonylureas (glipizide, glyburide) raise hypoglycemia risk; reduce their dose 50% when starting retatrutide.
- Insulin also raises hypoglycemia risk; reduce the insulin dose at retatrutide initiation.
- Other GLP-1 receptor agonists are redundant; discontinue them before starting retatrutide.
- With warfarin, the GLP-1 class may alter INR; monitor more frequently at dose changes.
- GLP-1-induced gastric delay may reduce oral contraceptive efficacy; consider non-oral contraception during active uptitration.
- Gastric delay may reduce acetaminophen (paracetamol) Cmax, usually not to a clinically significant degree.
- At dose changes, monitor any drug with a narrow therapeutic index that requires predictable absorption.
Specific populations requiring extra caution
- People with a history of depression or suicidal ideation need monitoring, since some GLP-1 class drugs have FDA adverse event signals for suicidality.
- A history of retinopathy calls for annual ophthalmology during rapid weight loss.
- After bariatric surgery, GLP-1 class data are limited and absorption may be altered.
Monitoring requirements
- At baseline, check fasting glucose, HbA1c, lipid panel, CMP, liver function, thyroid (TSH + free T4), blood pressure and resting heart rate (seated, post-rest), plus a pregnancy test in women of childbearing age and an eye exam if diabetic or high-risk.
- Every 4 weeks during uptitration, check fasting glucose, blood pressure, heart rate, weight and subjective tolerance.
- Every 12 weeks on maintenance, check HbA1c, liver function, lipids, weight and body composition.
- Annually, repeat the full panel plus a cardiovascular assessment, and ophthalmology if diabetic.
Discontinuation criteria
Stop retatrutide and consult a clinician on any of these:
- Severe persistent GI symptoms limiting food intake
- Any suspected pancreatitis symptoms (severe abdominal pain radiating to back)
- Severe hypoglycemia (glucose <54 mg/dL)
- Resting HR >100 bpm or new arrhythmia
- Severe depression or suicidal ideation
- Acute gallbladder symptoms
- Unexplained dehydration or electrolyte derangement
- Planning pregnancy
Detailed side effects
Common (10% or more)
- Nausea (dose-dependent, usually improves)
- Diarrhea
- Constipation
- Decreased appetite
- Vomiting (mostly during titration)
Less Common
- Increased heart rate
- Injection site reactions
- Fatigue
- Dizziness
- Dysesthesia (abnormal skin sensations, dose-related)
- Preclinical thyroid C-cell concerns
Contraindications
Interactions
4 pairings in our record: 2 to avoid and 2 with a caution.
Semaglutide
AvoidRetatrutide already includes GLP-1 agonism, so do not stack them.
Tirzepatide
AvoidOverlapping GLP-1 and GIP agonism makes this a dangerous combination.
MK-677
CautionMK-677 raises appetite and so opposes retatrutide's appetite suppression.
Cagrilintide
CautionAdditional amylin agonism may cause excessive appetite suppression
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailRetatrutide dosage and protocols
- Dose range
- 1,000–12,000 mcg (1–12 mg) per week
- Dosing
- Once weekly subcutaneous injection
- Common vials
- 5mg, 10mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Phase 2 titration schedule
- Weeks 1-21 mg/weekStarting dose
- Weeks 3-42 mg/weekFirst escalation
- Weeks 5-84 mg/weekIntermediate dose
- Weeks 9-128 mg/weekHigh dose
- Weeks 13-4812 mg/weekMaximum (if tolerated)
Caution. Do not skip titration.
05Prices
Retatrutide prices
11 listings from 5 vendors, opening in the Featured order.
- Pack prices
- $79.99 to $279.99
- Lowest per mg
- $8.00/mg
- Vendors
- 5
- Listings
- 11 (vial)
Prices as the vendors list them, last recorded 13 October 2026.
| Vendor | Product | Price | Buy |
|---|---|---|---|
RC-3R 10mg vial, 10mg vial In stock | $12.00/mg $119.99 | Buy RC-3R 10mg at ResearchChemHQ | |
BHG-3 10mg vial, 1 vial In stock | $12.00/mg $120.00 | Buy BHG-3 10mg at BHG Labs | |
Pep-3R 10mg (Retatrutide) vial, 1 vial In stock | $12.00/mg $119.99 | Buy Pep-3R 10mg (Retatrutide) at Optimum Formula | |
Retatrutide 10mg vial, 1 vial In stock | $10.00/mg $99.99 | Buy Retatrutide 10mg at BioMyst Labs | |
Retatrutide 10mg vial, 1 vial In stock | $12.00/mg $119.99 | Buy Retatrutide 10mg at BioMyst Labs | |
Retatrutide 20mg vial, 1 vial In stock | $8.00/mg $159.99 Lowest per mg | Buy Retatrutide 20mg at BioMyst Labs | |
Retatrutide 20mg vial, 1 vial In stock | $10.00/mg $199.99 | Buy Retatrutide 20mg at BioMyst Labs | |
GLP-Reta (Retatrutide) 5mg vial, 5mg vial In stock | $16.00/mg $79.99 | Buy GLP-Reta (Retatrutide) 5mg at Half Nattys | |
GLP-Reta (Retatrutide) 10mg vial, 10mg vial In stock | $12.00/mg $119.99 | Buy GLP-Reta (Retatrutide) 10mg at Half Nattys | |
GLP-Reta (Retatrutide) 15mg vial, 15mg vial In stock | $10.67/mg $159.99 | Buy GLP-Reta (Retatrutide) 15mg at Half Nattys | |
GLP-Reta (Retatrutide) 30mg vial, 30mg vial In stock | $9.33/mg $279.99 | Buy GLP-Reta (Retatrutide) 30mg at Half Nattys |
Vendors selling Retatrutide(5: trust score, certificates, payment, shipping)
- Half Nattys4 listings, from $79.99
Trust Score 50/100, 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US
- BioMyst Labs4 listings, from $99.99
Trust Score 70/100, no certificate records on file, pays by card, crypto, ships to the US, international destinations
- Optimum Formula1 listing, from $119.99
Trust Score 100/100, 4 of 6 certificate records read, pays by card, crypto, ships to the US
- ResearchChemHQ1 listing, from $119.99
Trust Score 100/100, 6 of 6 certificate records read, pays by card, crypto, ships to the US
- BHG Labs1 listing, from $120.00
Trust Score 100/100, 41 of 43 certificate records read, pays by card, crypto, ships to the US
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors
Price history(3 days with a recorded price)
06Chemistry
Chemistry and structure
- Molecular formula
- C221H342N46O68
- Molecular mass
- 4731 g/mol
- CAS number
- 2381294-46-4
- IUPAC name
- Not fully disclosed (Eli Lilly proprietary)
- Amino acid sequence
- 39-amino-acid synthetic peptide; GIP/GLP-1/glucagon triple receptor agonist (Eli Lilly LY3437943; CAS 2381089-83-2). Backbone (N->C, one-letter): YAQGTFTSDYSILLDKKAQAAFIEYLLEGGPSSGAPPPS. Key modifications (per the published structure): 2-aminoisobutyric acid (Aib) at positions 2 and 20; a C20 fatty diacid conjugated to a lysine side chain via a gamma-Glu/AEEA linker (albumin-binding moiety that extends the plasma half-life to ~6 days); C-terminal amidation. Molecular formula C221H342N46O68; molecular weight ~4731 g/mol.
08Questions
Frequently asked questions
What is retatrutide (LY3437943)?
Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It produced up to 24.2% weight loss at 48 weeks in Phase 2 and 28.3% at 80 weeks in the Phase 3 TRIUMPH-1 trial.
How does retatrutide differ from tirzepatide and semaglutide?
Semaglutide targets GLP-1 only. Tirzepatide targets GLP-1 + GIP (dual agonist). Retatrutide targets GLP-1 + GIP + glucagon (triple agonist). The glucagon receptor activation drives hepatic fat oxidation and can raise energy expenditure (shown in animal models and in short human glucagon studies, not yet published for retatrutide itself), mechanisms that neither semaglutide nor tirzepatide has.
What were the retatrutide Phase 2 trial results?
The Phase 2 trial (n=338) showed up to 24.2% mean body weight reduction with the 12mg dose at 48 weeks: 83% of that group lost at least 15% of their body weight and 26% lost 30% or more. In the trial's liver-fat substudy (98 participants with at least 10% liver fat), the 12mg dose cut liver fat by 86% at 48 weeks. The timepoints do not line up with the other trials: semaglutide's 14.9% came at 68 weeks in STEP-1 and tirzepatide's 22.5% at 72 weeks in SURMOUNT-1.
What are retatrutide's side effects?
Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite, similar to other GLP-1 agonists. Additional effects include increased heart rate, injection site reactions, fatigue, and dysesthesia (unpleasant abnormal skin sensations), which the Phase 3 trials reported in 4.4% to 20.9% of people on 12 mg against 0% to 1.3% on placebo. Preclinical thyroid concerns have been noted. Most GI side effects were dose-dependent and improved with titration.
What is the retatrutide dosing protocol?
Per the Phase 2 trial protocol: start at 1mg subcutaneous once weekly for 2 weeks, then titrate up through 2mg, 4mg, 8mg, and potentially 12mg over 24 weeks. The ~6-day half-life supports weekly dosing. Slow titration minimizes GI side effects.
Is retatrutide FDA approved?
No. Retatrutide is still investigational. Four of its Phase 3 TRIUMPH obesity trials have reported: TRIUMPH-4 in December 2025, TRIUMPH-1 in May 2026, TRIUMPH-2 and TRIUMPH-3 in July 2026. Others are still running, including TRIUMPH-5 against tirzepatide. Eli Lilly plans to submit it to the FDA in the first quarter of 2027, so any approval would come after that review. Outside those trials and Lilly's pre-approval expanded access program for severe obesity, it is available only as a research compound.
Can I stack retatrutide with semaglutide or tirzepatide?
No. Retatrutide already includes GLP-1 agonism. Stacking with semaglutide or tirzepatide would produce dangerous overlapping GLP-1 activity and is strongly contraindicated.
How many vendors sell Retatrutide, and what does it cost per mg?
5 of the vendors BodyHackGuide tracks list Retatrutide (11 listings). Among BodyHackGuide's Retatrutide listings recorded as in stock with a milligram count, the lowest price per milligram is $8.00/mg at BioMyst Labs and the median is $12.00/mg. The Retatrutide prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Retatrutide listing is dated 13 October 2026.
Which vendors have third-party COAs for Retatrutide on file at BodyHackGuide?
BodyHackGuide holds 952 third-party certificate records for Retatrutide, from Half Nattys and BHG Labs. An editor has read 1 of BodyHackGuide's 952 certificate records for Retatrutide and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's Retatrutide certificate records are Freedom Diagnostics Testing and ILS Laboratories, and the newest test date on them is 7 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Related
Articles on Retatrutide
- The 8 Best Peptide Companies for Research: 2026 Purity & Price Comparisonvendor-reviews, 16 September 2026
- Tesamorelin: A Complete Research ReferencePeptides, 1 July 2026
- Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works ForResearch, 20 May 2026
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.




